FELIPE NOVOA: Open Payments
NPI 1770905283 · MIAMI, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$30,121 in 89 payments from 14 companies in 2025. Trend: 2023 $19,483 · 2024 $40,085 · 2025 $30,121
Speaker / faculty: $17,280Travel & lodging: $8,578Food & beverage: $2,756Consulting: $1,508
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 60 | $25,443 |
| E.R. Squibb & Sons, L.L.C. | 6 | $2,506 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $1,403 |
| Novartis Pharmaceuticals Corporation | 2 | $228 |
| SOBI, INC | 3 | $93 |
| Celgene Corporation | 4 | $89 |
| GENZYME CORPORATION | 2 | $83 |
| Geron Corporation | 3 | $61 |
| Blueprint Medicines Corporation | 2 | $57 |
| Stemline Therapeutics Inc. | 2 | $51 |
Products named: OJJAARA, REBLOZYL, SCEMBLIX, AYVAKIT, RYTELO, Doptelet, ELZONRIS, clonoSEQ.
Industry payments across FL — which companies pay providers there.
